Introduction: The Synergy of Lipid Metabolism and Autophagy

Atherosclerosis remains a leading cause of cardiovascular mortality globally, including in India where the burden of metabolic diseases continues to rise. This chronic inflammatory condition involves the progressive accumulation of lipids and fibrous elements within the arterial wall. Recent research highlights that the development of atherosclerosis is intrinsically linked to disorders in lipid metabolism and the subsequent dysfunction of autophagy. Autophagy acts as a cellular recycling mechanism that maintains homeostasis by clearing damaged organelles and excess lipids. When this process fails, it exacerbates plaque formation and stability issues. Identifying specific atherosclerosis lipid metabolism regulators is therefore essential for developing targeted therapeutic strategies. Scientists recently focused on discovering the hub genes that bridge these two critical pathways. By integrating advanced bioinformatics with experimental validation, this study pinpointed three core regulators: PRKCB, NLRC4, and TNFSF10. These findings offer a significant leap forward in understanding how cellular self-cleaning and lipid handling intersect during the progression of arterial plaques.

Identification of the Core Regulatory Trio

To identify the primary genetic drivers of the lipid metabolism-autophagy network, researchers employed a sophisticated multi-omic approach. Initially, they integrated bulk transcriptome data with single-cell RNA sequencing to screen for differentially expressed genes in atherosclerotic tissues. Furthermore, the team utilized Weighted Gene Co-expression Network Analysis (WGCNA) to identify specific gene modules that correlated strongly with both lipid handling and autophagic processes. Subsequently, a machine learning algorithm known as LASSO regression further narrowed the selection to the most significant core regulatory genes. This rigorous screening process successfully identified PRKCB, NLRC4, and TNFSF10 as the most influential factors. These genes appear to orchestrate a complex network that governs how cells within the plaque environment respond to lipid-induced stress. Moreover, the expression patterns of these genes were remarkably consistent across multiple datasets, reinforcing their status as key regulators. Consequently, these molecules represent promising candidates for further investigation as clinical biomarkers. By focusing on these specific genetic markers, clinicians might eventually gain better diagnostic insights into individual plaque vulnerability and metabolic status.

Immune Microenvironment and Cellular Distribution Patterns

The immune microenvironment of an atherosclerotic plaque is incredibly heterogeneous and plays a decisive role in disease progression. This study calculated the enrichment scores for 28 distinct immune cell subtypes using single-sample Gene Set Enrichment Analysis (ssGSEA). Interestingly, the results showed a strong correlation between the identified core genes and specific immune infiltration characteristics. Specifically, Spearman correlation analysis revealed that the expression levels of PRKCB, NLRC4, and TNFSF10 were significantly associated with the presence of inflammatory cells. Furthermore, single-cell transcriptome data allowed the researchers to map these genes to specific cell subpopulations within the plaque. Notably, macrophage subpopulations exhibited the highest regulatory activity within the lipid metabolism-autophagy network. These findings suggest that these genes primarily function within macrophages to regulate how they handle lipid overload and inflammation. Additionally, the distribution patterns of these regulators varied across different cell types, including endothelial cells and smooth muscle cells. Therefore, understanding these cellular patterns is crucial for developing cell-specific therapies that could stabilize plaques. Such insights provide a deeper understanding of the immunological landscape of atherosclerosis.

Atherosclerosis Lipid Metabolism Regulators and Molecular Docking

Targeting specific proteins involved in the lipid metabolism-autophagy network requires identifying molecules that can effectively modulate their activity. In this study, the researchers screened potential drugs from public databases that might target the identified hub genes. Specifically, they focused on PRKCB due to its central role in the identified network. Molecular docking technology allowed the team to simulate how approved drugs might bind to the active site of the PRKCB protein. Consequently, they discovered that two well-known drugs, quercetin and atenolol, could stably bind to PRKCB. Quercetin, a natural flavonoid with known anti-atherosclerotic properties, demonstrated a strong docking energy of -8.3 kcal/mol. Similarly, the beta-blocker atenolol showed a stable binding energy of -6.2 kcal/mol. These results indicate that PRKCB is a highly druggable target worthy of clinical attention. Furthermore, the ability of these common medications to interact with a key regulator of lipid metabolism and autophagy suggests a potential mechanism for their cardiovascular benefits. Moreover, these findings highlight the possibility of repurposing existing drugs to better manage atherosclerotic progression by targeting the core atherosclerosis lipid metabolism regulators identified in this research.

Experimental Validation of Hub Gene Expression

To confirm the clinical relevance of PRKCB, NLRC4, and TNFSF10, the researchers conducted extensive experimental validation using mouse models of atherosclerosis. Initially, they utilized quantitative real-time PCR (RT-qPCR) and Western blotting to measure the expression of these target factors in aortic tissues. The data consistently showed that all three genes were significantly elevated in atherosclerotic plaque tissue compared to healthy controls. Furthermore, immunohistochemical (IHC) analysis provided visual confirmation of the increased protein levels within the lesions. Specifically, the expression of these factors was most prominent in areas rich in lipid deposits and inflammatory cells. In addition to tissue-level changes, the study also examined systemic markers. Consequently, enzyme-linked immunosorbent assay (ELISA) testing confirmed that TNFSF10 levels were significantly higher in the plasma of atherosclerotic mice. This systemic elevation suggests that TNFSF10 could potentially serve as a non-invasive circulating biomarker for the disease. Ultimately, the combination of bioinformatics and laboratory evidence provides a robust foundation for the role of these genes in AS. These validated markers could revolutionize how we monitor disease activity in high-risk patients.

Conclusion: Therapeutic and Diagnostic Potential

In conclusion, this research successfully identifies PRKCB, NLRC4, and TNFSF10 as the core regulatory hub genes linking lipid metabolism and autophagy in atherosclerosis. These genes are not only significantly associated with the plaque's immune microenvironment but also exhibit specific cellular distribution patterns, particularly within macrophages. The molecular docking results for quercetin and atenolol further highlight PRKCB as a viable therapeutic target. Moreover, the experimental validation in mouse models confirms the diagnostic potential of these factors, especially the plasma-detectable TNFSF10. By targeting these atherosclerosis lipid metabolism regulators, future treatments could potentially restore autophagic function and improve lipid clearance within arterial walls. Consequently, these findings offer a new framework for both the early diagnosis and the personalized treatment of cardiovascular diseases. Clinicians should remain attentive to future studies that translate these molecular targets into bedside applications.

Frequently Asked Questions

How do PRKCB, NLRC4, and TNFSF10 impact the development of atherosclerosis?

These three genes act as central regulators that bridge lipid metabolism disorders and autophagic dysfunction. In atherosclerosis, they help coordinate how cells, particularly macrophages, process excess cholesterol and clear damaged cellular components. When these genes are overexpressed or dysregulated, they influence inflammatory responses and plaque stability. By understanding their specific roles, researchers can develop strategies to restore metabolic balance and slow down the progression of arterial lesions in high-risk cardiovascular patients.

What role does the immune microenvironment play in the regulation of these atherosclerotic hub genes?

The immune microenvironment within a plaque consists of various cell types that interact with the genetic network of PRKCB, NLRC4, and TNFSF10. These genes are strongly correlated with the infiltration of specific immune cell subtypes, such as macrophages and T-cells. Specifically, macrophages show the highest activity in the lipid metabolism-autophagy network. The interplay between these genes and immune cells determines the inflammatory state of the plaque, which ultimately influences whether a lesion remains stable or becomes vulnerable to rupture.

Can existing drugs like quercetin or atenolol truly help in targeting these genetic regulators?

Molecular docking studies show that both quercetin and atenolol can bind stably to the active site of the PRKCB protein. This suggests that these medications might exert their anti-atherosclerotic effects, at least in part, by modulating this key regulator of the lipid-autophagy network. While further clinical trials are necessary to confirm these mechanisms in humans, these findings open up exciting possibilities for drug repurposing and the development of more targeted therapies that focus on stabilizing metabolic pathways within the arterial wall.

Disclaimer: This content is for informational and educational purposes only. It is not intended to provide specific medical advice or to substitute for the advice of a qualified healthcare professional. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Li M et al. Identification of PRKCB, NLRC4, and TNFSF10 as Key Regulators of the Lipid Metabolism-Autophagy Network in Atherosclerosis. Cell Biochem Funct. 2026 Jul undefined. doi: 10.1002/cbf.70221. PMID: 42389891.

Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011;17(11):1410-1422.

Shao BZ et al. Autophagy in Atherosclerotic Plaque Cells: Targeting NLRP3 Inflammasome for Self-Rescue. Front Pharmacol. 2016;7:420.